Treatment of hereditary angioedema with plasma-derived C1 inhibitor
نویسندگان
چکیده
منابع مشابه
Treatment of hereditary angioedema with plasma-derived C1 inhibitor
BACKGROUND Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA. OBJECTIVE To review the medical literature to determine if ...
متن کاملDiagnosis and treatment of hereditary angioedema with normal C1 inhibitor
Until recently it was assumed that hereditary angioedema is a disease that results exclusively from a genetic deficiency of the C1 inhibitor. In 2000, families with hereditary angioedema, normal C1 inhibitor activity and protein in plasma were described. Since then numerous patients and families with that condition have been reported. Most of the patients by far were women. In many of the affec...
متن کاملC1-inhibitor concentrate for treatment of hereditary angioedema.
BACKGROUND Hereditary angioedema due to C1 inhibitor deficiency is characterized by recurrent acute attacks of swelling that can be painful and sometimes life-threatening. METHODS We conducted two randomized trials to evaluate nanofiltered C1 inhibitor concentrate in the management of hereditary angioedema. The first study compared nanofiltered C1 inhibitor concentrate with placebo for treatm...
متن کاملCinryze, a human plasma-derived c1 esterase inhibitor for prophylaxis of hereditary angioedema.
Vol. 34 No. 6 • June 2009 • P&T® 293 INTRODUCTION Hereditary angioedema (HAE) is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor (C1-INH), a molecule that inhibits kallikrein and other serine proteinases. HAE is characterized by un predictable and recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and l...
متن کامل163 The Efficacy of Human Plasma-Derived C1-Inhibitor Concentrate Used for Prophylactic Treatment in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency
vidual rhinoconjunctivitis symptom scores. The primary efficacy endpoint, the daily CS during the pollen period while on treatment, was analyzed using a repeated measures ANCOVA model, as were the above secondary efficacy endpoints. The safety of the treatment was documented by means of adverse event reporting, laboratory data and physical examination findings. Results: The 300IR group showed a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2008
ISSN: 1178-203X
DOI: 10.2147/tcrm.s3172